Related Experiment Video
Updated: Aug 8, 2026
08:58
Fully Automated Centrifugal Microfluidic Device for Ultrasensitive Protein Detection from Whole Blood
Published on: April 16, 2016
A novel immunoadsorption device for removing beta2-microglobulin from whole blood
G A Ameer1, E A Grovender, H Ploegh
1Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA. gameer@mit.edu
Kidney International
|March 22, 2001
Summary
This study demonstrates that immunoadsorption using a Vortex Flow Plasmapheretic Reactor effectively removes beta2-microglobulin (beta2m), a key factor in dialysis-related amyloidosis. This specific approach shows promise for improving patient outcomes in end-stage renal disease.
Area of Science:
- Nephrology
- Biomedical Engineering
- Immunology
Background:
- High plasma beta2-microglobulin (beta2m) is linked to dialysis-related amyloidosis (DRA).
- Conventional renal replacement therapies inadequately remove beta2m due to nonspecific mechanisms.
- Nonspecific removal hinders understanding of middle molecule roles in end-stage renal disease (ESRD) pathology.
Purpose of the Study:
- To evaluate the efficacy of a specific immunoadsorption approach for beta2m removal.
- To assess the performance of a Vortex Flow Plasmapheretic Reactor (VFPR) utilizing anti-beta2m antibodies.
- To determine if specific beta2m targeting can prevent loss of other essential proteins.
Main Methods:
- Utilized agarose-immobilized murine anti-human beta2m monoclonal antibodies in a VFPR.
- Hemoperfused human blood in an extracorporeal circuit at 200 mL/min for two hours.
- Tested removal of baseline and controlled recombinant beta2m concentrations.
Main Results:
- Immunoadsorbent media exhibited a binding site density of 30 microg beta2m/mL.
- VFPR cleared baseline beta2m to undetectable levels.
- Achieved 92% beta2m clearance within 20 minutes for higher concentrations.
- No adverse hemocompatibility issues were observed.
Conclusions:
- The VFPR demonstrates optimal adsorptive kinetics for beta2m removal under tested conditions.
- Immunoadsorption is a viable strategy for targeting and reducing beta2m levels.
- This specific approach supports further investigation for managing DRA and ESRD morbidities.
